NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.
You may also be interested in...
OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
Safety study of celecoxib vs. ibuprofen and naproxen spurs advisory committees to recommend adding aspirin-interaction warning on OTC naproxen labels, but many panelist made clear that PRECISION results had not swayed their thinking on celecoxib CV safety or on the OTC ingredients' interaction with aspirin.
OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
Safety study of celecoxib vs. ibuprofen and naproxen spurs advisory committees to recommend adding aspirin-interaction warning on OTC naproxen labels, but many panelist made clear that PRECISION results had not swayed their thinking on celecoxib CV safety or on the OTC ingredients' interaction with aspirin.
NSAID Comparative Safety: PRECISION Study, FDA Pertinacity … And Anti-Clotting Agents?
US FDA's planned advisory committee on comparative safety in the NSAID/COX inhibitor area shows agency's staying power on safety issues.